| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 58.47K | 2.52M |
| Revenue Growth % | - | - | - | - | - | 42.17% |
| Cost of Goods Sold | 573 | 3.06K | 4.89K | 6.75K | 1.19M | 1.47M |
| COGS % of Revenue | - | - | - | - | 20.28% | 0.58% |
| Gross Profit | -573 | -3.06K | -4.89K | -6.75K | -1.13M | 1.06M |
| Gross Margin % | - | - | - | - | -19.28% | 0.42% |
| Gross Profit Growth % | - | -4.33% | -0.6% | -0.38% | -165.94% | 1.94% |
| Operating Expenses | 879.66K | 1.62M | 3.42M | 13.48M | 34.91M | 57.54M |
| OpEx % of Revenue | - | - | - | - | 597.07% | 22.8% |
| Selling, General & Admin | 819.49K | 1.1M | 2.09M | 9.35M | 14.77M | 11.23M |
| SG&A % of Revenue | - | - | - | - | 252.64% | 4.45% |
| Research & Development | 60.17K | 524.91K | 1.33M | 4.13M | 1.95M | 154.36K |
| R&D % of Revenue | - | - | - | - | 33.34% | 0.06% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 18.19M | 46.16M |
| Operating Income | -880.23K | -1.62M | -3.42M | -13.48M | -36.03M | -56.49M |
| Operating Margin % | - | - | - | - | -616.34% | -22.38% |
| Operating Income Growth % | - | -0.84% | -1.11% | -2.94% | -1.67% | -0.57% |
| EBITDA | -879.66K | -1.62M | -3.41M | -13.47M | -35.99M | -55.76M |
| EBITDA Margin % | - | - | - | - | -615.59% | -22.09% |
| EBITDA Growth % | - | -0.84% | -1.11% | -2.95% | -1.67% | -0.55% |
| D&A (Non-Cash Add-back) | 573 | 3.06K | 4.89K | 6.75K | 43.94K | 731.35K |
| EBIT | -821.91K | -1.6M | -3.42M | -13.42M | -36.75M | -58.33M |
| Net Interest Income | 58.32K | 22.6K | 0 | 0 | -671.63K | -1.41M |
| Interest Income | 58.32K | 22.6K | 0 | 0 | 0 | 18 |
| Interest Expense | 0 | 0 | 0 | 0 | 671.63K | 1.41M |
| Other Income/Expense | 58.32K | 22.6K | 0 | 61.41K | -1.39M | -3.25M |
| Pretax Income | -821.91K | -1.6M | -3.42M | -13.42M | -37.42M | -59.74M |
| Pretax Margin % | - | - | - | - | -640.08% | -23.67% |
| Income Tax | 0 | 0 | 0 | 0 | -12.59K | -1.05M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.98% |
| Net Income | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M |
| Net Margin % | - | - | - | - | -639.86% | -23.25% |
| Net Income Growth % | - | -0.95% | -1.14% | -2.93% | -1.79% | -0.57% |
| Net Income (Continuing) | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 7.01M | 0 |
| EPS (Diluted) | -0.07 | -0.14 | -0.31 | -1.09 | -87.60 | -1823.25 |
| EPS Growth % | - | -0.88% | -1.21% | -2.52% | -79.37% | -19.81% |
| EPS (Basic) | -0.07 | -0.14 | -0.31 | -1.09 | -87.60 | -1823.25 |
| Diluted Shares Outstanding | 3.25K | 3.25K | 3.25K | 3.61K | 5.03K | 32.3K |
| Basic Shares Outstanding | 3.25K | 3.25K | 3.25K | 3.61K | 5.03K | 32.3K |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 6.06M | 4.6M | 3.07M | 26.26M | 5.84M | 950.27K |
| Cash & Short-Term Investments | 6.05M | 4.31M | 1.93M | 25.75M | 4.55M | 646.5K |
| Cash Only | 6.05M | 4.31M | 1.93M | 25.75M | 4.55M | 646.5K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.33K | 44.8K | 152.52K | 35.85K | 149.73K | 96.31K |
| Days Sales Outstanding | - | - | - | - | 934.78 | 13.93 |
| Inventory | 0 | 0 | 0 | 0 | 364.05K | 64.08K |
| Days Inventory Outstanding | - | - | - | - | 112.07 | 15.92 |
| Other Current Assets | 0 | 0 | 757.65K | 0 | 0 | 0 |
| Total Non-Current Assets | 21.93K | 215.6K | 11.5K | 52.71K | 81.68M | 27.23M |
| Property, Plant & Equipment | 6.93K | 15.67K | 11.5K | 14.09K | 209.2K | 182.32K |
| Fixed Asset Turnover | - | - | - | - | 0.28x | 13.84x |
| Goodwill | 0 | 0 | 0 | 0 | 55.68M | 27.05M |
| Intangible Assets | 0 | 0 | 0 | 0 | 25.41M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 250.31K |
| Other Non-Current Assets | 15K | 199.93K | 0 | 38.62K | 383.54K | -250.31K |
| Total Assets | 6.08M | 4.81M | 3.08M | 26.31M | 87.52M | 28.18M |
| Asset Turnover | - | - | - | - | 0.00x | 0.09x |
| Asset Growth % | - | -0.21% | -0.36% | 7.53% | 2.33% | -0.68% |
| Total Current Liabilities | 75.76K | 68.67K | 1.64M | 3.92M | 17.19M | 18.29M |
| Accounts Payable | 18.38K | 68.67K | 582.61K | 1.5M | 5.3M | 3.79M |
| Days Payables Outstanding | 11.71K | 8.2K | 43.49K | 81.05K | 1.63K | 941.08 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 9.62M | 9.33M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 234.26K | 1.15M | 490.22K | 230.04K |
| Current Ratio | 79.98x | 66.94x | 1.88x | 6.69x | 0.34x | 0.05x |
| Quick Ratio | 79.98x | 66.94x | 1.88x | 6.69x | 0.32x | 0.05x |
| Cash Conversion Cycle | - | - | - | - | -583.26 | -911.23 |
| Total Non-Current Liabilities | 6.86K | 9.64K | 0 | 0 | 68.92M | 280.88K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 118.86K | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 74.29K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 3.07M | 0 |
| Other Non-Current Liabilities | 6.86K | 9.64K | 0 | 0 | 65.66M | 280.88K |
| Total Liabilities | 82.62K | 78.31K | 1.64M | 3.92M | 86.11M | 18.57M |
| Total Debt | 0 | 0 | 0 | 0 | 9.89M | 9.45M |
| Net Debt | -6.05M | -4.31M | -1.93M | -25.75M | 5.33M | 8.8M |
| Debt / Equity | - | - | - | - | 7.04x | 0.98x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -53.65x | -40.13x |
| Total Equity | 6M | 4.73M | 1.45M | 22.39M | 1.4M | 9.61M |
| Equity Growth % | - | -0.21% | -0.69% | 14.48% | -0.94% | 5.84% |
| Book Value per Share | 1846.23 | 1456.99 | 445.24 | 6203.38 | 279.11 | 297.54 |
| Total Shareholders' Equity | 6M | 4.73M | 1.45M | 22.39M | -5.6M | 9.61M |
| Common Stock | 8 | 32 | 32 | 157 | 6 | 118 |
| Retained Earnings | -939.87K | -2.54M | -5.96M | -19.38M | -56.79M | -115.68M |
| Treasury Stock | 0 | 0 | 0 | -566.81K | -625.79K | -625.79K |
| Accumulated OCI | -8 | 0 | 0 | 0 | 2.38M | -2.72M |
| Minority Interest | 0 | 0 | 0 | 0 | 7.01M | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -825.13K | -1.73M | -2.04M | -8.68M | -13.58M | -10.5M |
| Operating CF Margin % | - | - | - | - | -232.29% | -4.16% |
| Operating CF Growth % | - | -1.1% | -0.18% | -3.24% | -0.57% | 0.23% |
| Net Income | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M |
| Depreciation & Amortization | 573 | 3.06K | 4.89K | 6.75K | 43.94K | 731.35K |
| Stock-Based Compensation | 3.27K | 334.84K | 130.14K | 1.97M | 329.76K | 438.65K |
| Deferred Taxes | 0 | -292.13K | 0 | 0 | -12.59K | -1.05M |
| Other Non-Cash Items | 0 | 292.13K | 23.44K | 202.51K | 21.84M | 49.61M |
| Working Capital Changes | -7.05K | -468.56K | 1.21M | 2.56M | 1.62M | -1.54M |
| Change in Receivables | -8.33K | -1.48K | -114.96K | 0 | -62.29K | 116.68K |
| Change in Inventory | 0 | 1.48K | 0 | 0 | -315.83K | -62.27K |
| Change in Payables | 18.38K | 50.29K | 336.71K | 1.09M | 3.37M | -1.48M |
| Cash from Investing | -4.5K | -11.79K | -1.92K | -32.66K | -8.65M | -28.47K |
| Capital Expenditures | -4.5K | -11.79K | -1.92K | -9.34K | -55.04K | -28.47K |
| CapEx % of Revenue | - | - | - | - | 0.94% | 0.01% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -23.33K | -8.59M | 0 |
| Cash from Financing | 6.88M | 0 | -334.19K | 32.53M | 1.04M | 6.74M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -206.4K |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -334.19K | -1.77M | -204.63K | -187.28K |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -829.63K | -1.74M | -2.05M | -8.68M | -13.64M | -10.52M |
| FCF Margin % | - | - | - | - | -233.23% | -4.17% |
| FCF Growth % | - | -1.1% | -0.17% | -3.24% | -0.57% | 0.23% |
| FCF per Share | -255.35 | -536.14 | -629.78 | -2406.45 | -2709.87 | -325.83 |
| FCF Conversion (FCF/Net Income) | 1.00x | 1.08x | 0.60x | 0.65x | 0.36x | 0.18x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 379.41K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -13.7% | -29.81% | -110.59% | -112.61% | -314.47% | -1065.65% |
| Return on Invested Capital (ROIC) | - | -653.01% | - | - | -1603.32% | -336.95% |
| Gross Margin | - | - | - | - | -1927.93% | 41.8% |
| Net Margin | - | - | - | - | -63986.48% | -2325.21% |
| Debt / Equity | - | - | - | - | 7.04x | 0.98x |
| Interest Coverage | - | - | - | - | -53.65x | -40.13x |
| FCF Conversion | 1.00x | 1.08x | 0.60x | 0.65x | 0.36x | 0.18x |
| Revenue Growth | - | - | - | - | - | 4217.31% |
| 2023 | 2024 | |
|---|---|---|
| European Union | - | 2.44M |
| European Union Growth | - | - |
| UNITED STATES | - | 63.12K |
| UNITED STATES Growth | - | - |
| SWITZERLAND | 58.47K | - |
| SWITZERLAND Growth | - | - |
Onconetix, Inc. (ONCO) reported $1.2M in revenue for fiscal year 2024.
Onconetix, Inc. (ONCO) grew revenue by 4217.3% over the past year. This is strong growth.
Onconetix, Inc. (ONCO) reported a net loss of $49.1M for fiscal year 2024.
Yes, Onconetix, Inc. (ONCO) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Onconetix, Inc. (ONCO) has a return on equity (ROE) of -1065.7%. Negative ROE indicates the company is unprofitable.
Onconetix, Inc. (ONCO) had negative free cash flow of $7.5M in fiscal year 2024, likely due to heavy capital investments.